About the Symposium
This practical workshop will focus on initial Pediatric Study Plan (iPSP) and Paediatric Investigation Plan (PIP) development and implementation in today's rapidly changing pediatric cancer landscape.
In this unique forum, attendees from academia, industry, and regulatory agencies will discuss real-life examples and real-world lessons to meet new FDARA guidelines and support early pediatric drug development.
Recognizing the importance of event networking opportunities, our virtual platform will also provide opportunities for one on one and group networking in an engaging online environment. Participants will return to their company or institution with tactical learnings, new relationships, and a better understanding of developing a successful iPSP/PIP.
Who Should Attend
Industry leaders, academics and other thought leaders in pediatric drug development including:
Research and Development
Academic/Key Opinion Leaders
Pediatric Study Plan development is a team and multi-function effort. To maximize learnings and ensure proper early plan development for pediatrics, 3-5 representatives from the same company should participate.
Samuel C. Blackman, MD, PhD
Chief Medical Officer & Co-Founder
Day One Biopharmaceuticals
Brenda Weigel, MD
Director of the Division of Pediatric Hematology/Oncology
University of Minnesota's Masonic Cancer Center
For additional information, please contact Kelli Wright at email@example.com or (240) 235-2217.